Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 26

Results For "diseases"

1271 News Found

Resolution Therapeutics doses first patient in phase I/II Emerald study of RTX001 for end-stage liver disease
Clinical Trials | September 05, 2025

Resolution Therapeutics doses first patient in phase I/II Emerald study of RTX001 for end-stage liver disease

RTX001 represents a groundbreaking advance in the treatment of end-stage liver disease, offering new hope for patients with limited options


FDA approves Sanofi’s BTK inhibitor for immune thrombocytopenia
Drug Approval | September 02, 2025

FDA approves Sanofi’s BTK inhibitor for immune thrombocytopenia

ITP is a disease of complex immune dysregulation leading to low platelet counts, bleeding, and reduced quality of life


Zydus launches VaxiFlu vaccine for flu protection
News | September 02, 2025

Zydus launches VaxiFlu vaccine for flu protection

First Indian company to follow global recommendations in accordance with the World Health Organisation (WHO)


Novo Nordisk taps Replicate Bioscience’s srRNA platform for obesity
News | August 31, 2025

Novo Nordisk taps Replicate Bioscience’s srRNA platform for obesity

Replicate will receive research funding and could potentially receive up to approximately US$550 million


Accro Bioscience and Fosun Pharma ink agreement for TYK2/JAK1 Inhibitor in Greater China
News | August 30, 2025

Accro Bioscience and Fosun Pharma ink agreement for TYK2/JAK1 Inhibitor in Greater China

Accro will retain global rights to develop, manufacture, and commercialize AC-201 (excluding Chinese Mainland, Hong Kong SAR, and Macau SAR)


Lighthouse receives $49.2 million NIA grant to advance phase 2 study of Alzheimer’s disease
News | August 28, 2025

Lighthouse receives $49.2 million NIA grant to advance phase 2 study of Alzheimer’s disease

LHP588 is an oral, brain-penetrant lysine-gingipain (Kgp) inhibitor designed to block the key virulence factor of P. gingivalis


FDA approves Coya Therapeutics’ trial of COYA 302 for ALS
News | August 28, 2025

FDA approves Coya Therapeutics’ trial of COYA 302 for ALS

As part of its partnership with Dr. Reddy’s Laboratories (DRL), FDA acceptance also triggers a $4.2 million milestone payment to Coya


India releases first-ever National Guidelines/SOPs for animal blood transfusion and blood banks
News | August 26, 2025

India releases first-ever National Guidelines/SOPs for animal blood transfusion and blood banks

Guidelines aim to establish state-regulated veterinary blood banks


Enanta files patent infringement suit against Pfizer
News | August 25, 2025

Enanta files patent infringement suit against Pfizer

The ‘265 Patent is based on Enanta’s July 2020 patent application describing coronavirus protease inhibitors invented by Enanta scientists


FDA grants ODD to Keros KER-065 for treatment of Duchenne muscular dystrophy
Drug Approval | August 25, 2025

FDA grants ODD to Keros KER-065 for treatment of Duchenne muscular dystrophy

KER-065 is a novel ligand trap comprised of a modified ligand-binding domain derived from activin receptor type IIA and activin receptor type IIB